Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
90 participants
INTERVENTIONAL
2022-12-15
2022-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neutrophil Gelatinase-associated Lipocalin Concentration in Coronary Artery Disease
NCT00749281
Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
NCT02616705
Serum NGAL IN Patients With Multiple Myeloma
NCT05439538
Diagnostic and Prognostic Biomarkers for IgG4-related Disease.
NCT05901207
Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia
NCT05371392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
group of vitiligo patients
NGAL
Serum NGAL in blood for early detection of CVR
control group
healthy group
NGAL
Serum NGAL in blood for early detection of CVR
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NGAL
Serum NGAL in blood for early detection of CVR
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doaa Gamal Hafez
resident doctor at dermatology department sohag university hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag fuculty
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Marwa M Abd El-Meged, professor
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15.
Vachiramon V, Onprasert W, Harnchoowong S, Chanprapaph K. Prevalence and Clinical Characteristics of Itch in Vitiligo and Its Clinical Significance. Biomed Res Int. 2017;2017:5617838. doi: 10.1155/2017/5617838. Epub 2017 Jul 30.
Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013 Feb;149(2):159-64. doi: 10.1001/jamadermatol.2013.927.
Mazzei Weiss ME. Vitiligo: to biopsy or not to biopsy? Cutis. 2020 Apr;105(4):189-190. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-21-10-20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.